All In Biotech

Drug Trial Radar · NCT01860482

The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD

An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen

Last checked: Nov 20, 2026Latest source record: Sep 24, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

39

Actual

Start

Apr 2013

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Chong Kun Dang PharmaceuticalIndustry
Sponsor type
Industry
First posted
May 22, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of Newrabell® Tab. in patients with refractory reflux esophagitis to the prior standard PPIs regimen.

Conditions

  • Reflux Esophagitis

Interventions

  • Newrabell® Tablet 10mgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to onset of first 1Day Heartburn free, DaysTime frame: up to 8 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Chonnam National University Hospital

    Gwangju, Donggu, Jebongro, South Korea

  • Chonnam National University Hwasun Hospital

    Gwangju, Hwasun-eup,Hwasun-gun, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.